HIV-1 Reservoir Study: ITACO and ITACO-ATI

We are investigating how the HIV-1 virus behaves in patients with perinatal infections to find better treatment strategies. This study looks at the effects of temporarily stopping antiretroviral therapy and the immune responses involved.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Abacavir
Abacavir is a substance that helps prevent HIV from multiplying, reducing the amount of virus in the body.
Cobicistat
Cobicistat is a substance that boosts levels of certain HIV treatments by slowing their breakdown in the body.
Darunavir
Darunavir is a substance that helps control HIV by blocking a viral enzyme needed for the virus to reproduce.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Ospedale Pediatrico Bambino Gesu
Immunologia clinica e vaccinologia
Rome, Italy
Sponsor: Ospedale Pediatrico Bambino Gesu
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.